| Title |
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
|
|---|---|
| Published in |
Investigational New Drugs, September 2010
|
| DOI | 10.1007/s10637-010-9538-8 |
| Pubmed ID | |
| Authors |
Katalin Boér, István Láng, Antonio Llombart-Cussac, Inger Andreasson, Guillermo L. Vivanco, Nick Sanders, Gillian M. Pover, Elizabeth Murray |
| Abstract |
The aim of this Phase II study was to assess the efficacy and safety of vandetanib in combination with docetaxel in patients with pretreated advanced breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| France | 1 | 2% |
| Unknown | 60 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 23% |
| Student > Master | 10 | 16% |
| Student > Ph. D. Student | 8 | 13% |
| Other | 7 | 11% |
| Student > Doctoral Student | 3 | 5% |
| Other | 10 | 16% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 26% |
| Agricultural and Biological Sciences | 5 | 8% |
| Psychology | 4 | 6% |
| Economics, Econometrics and Finance | 4 | 6% |
| Nursing and Health Professions | 3 | 5% |
| Other | 12 | 19% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2012.
All research outputs
#20,159,700
of 22,668,244 outputs
Outputs from Investigational New Drugs
#975
of 1,164 outputs
Outputs of similar age
#90,226
of 95,074 outputs
Outputs of similar age from Investigational New Drugs
#23
of 24 outputs
Altmetric has tracked 22,668,244 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,164 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,074 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.